PARD6A

Across TCGA pan-cancer cohorts, PARD6A RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated PARD6A data layer compared with 4 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PARD6A RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated PARD6A expression acts as an unfavorable survival marker, although some lineages such as STAD and HNSC show a favorable association.

STAD, HNSC, and BRCA are the cancer types where PARD6A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.674	0.426	<.001	122	view →
HNSC	OS	Median	IV	0.782	0.629	<.001	96	view →
BRCA	DFS	Median	II,III,IV	0.584	0.483	<.001	58	view →
LGG	DFS	Median	All	0.818	0.656	<.001	53	view →
UCS	OS	Tertile	II,III,IV	0.375	0.810	.006	50	view →
KIRP	DFS	Median	IV	0.035	0.527	.001	36	view →
OV	DFS	Median	IV	0.414	0.206	.001	32	view →
LIHC	DFS	Median	All	0.484	0.597	.006	20	view →
UCEC	DFS	Median	II,III,IV	0.709	0.378	.011	18	view →
READ	DFS	Tertile	All	0.775	0.548	.011	18	view →
SARC	OS	Tertile	All	0.819	0.661	.011	18	view →
LUSC	DFS	Tertile	II,III,IV	0.487	0.690	.006	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

PARD6A–STAD (DFS)

Open the STAD breakdown →